Review of Data from the ASCO 2020 Virtual Meeting

EP. 1: Metastatic HR+ Breast Cancer Updates

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

EP. 2: ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

EP. 3: Metastatic Triple-Negative Breast Cancer Ongoing Trials

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

EP. 4: Perioperative Therapy: ASCO 2020 Data Updates

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026